➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Baxter
Johnson and Johnson
Moodys
Medtronic

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,835,474

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,835,474 protect, and when does it expire?

Patent 8,835,474 protects MYRBETRIQ and is included in one NDA.

This patent has thirty-two patent family members in twenty-five countries.

Summary for Patent: 8,835,474
Title:Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Abstract: (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or its salt shows a potent bladder relaxation effect in "isolated rat bladder smooth muscle relaxation test", dose-dependently lowers the contraction frequency of rhythmic bladder contractions in "rat rhythmic bladder contraction measurement test" and, moreover, prolongs the urination intervals in "urination functions measurement test on cyclophosphamide-induced overactive bladder model rat". Owing to these effects, the above compound is useful as a remedy for overactive bladder.
Inventor(s): Takasu; Toshiyuki (Tsukubamirai, JP), Sato; Shuichi (Tsukuba, JP), Ukai; Masashi (Tsukuba, JP), Maruyama; Tatsuya (Tsuchiura, JP), Shibasaki; Masayuki (Tokyo, JP)
Assignee: Astellas Pharma Inc. (Tokyo, JP)
Application Number:13/117,638
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,835,474
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 8,835,474

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Apgdi MYRBETRIQ mirabegron TABLET, EXTENDED RELEASE;ORAL 202611-001 Jun 28, 2012 RX Yes Yes   Start Trial   Start Trial FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY   Start Trial
Apgdi MYRBETRIQ mirabegron TABLET, EXTENDED RELEASE;ORAL 202611-002 Jun 28, 2012 RX Yes Yes   Start Trial   Start Trial FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,835,474

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2002-323792Nov 7, 2002

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKinsey
AstraZeneca
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.